Physician profile
Marc Seelagy
NPI 1336195056
$8,173.93
in general payments reported to CMS, 2019-2025
41 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 82% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $589 · 2021: $1,052 · 2022: $1,173 · 2023: $1,718 · 2024: $1,112 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,113 · Education: $97.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,112.56 |
| Education | $97.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,172.90 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,007.25 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $623.66 | 2019-2025 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Mylan Specialty L.P. | $376.57 | 2019-2024 | Yupelri |
| Harmony Biosciences LLC | $370.37 | 2020-2025 | Wakix |
| Philips North America LLC | $302.14 | 2019-2023 | |
| Genzyme Corporation | $272.54 | 2019-2025 | |
| Axsome Therapeutics, INC. | $208.26 | 2023-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $183.65 | 2021-2025 | Dupixent |
| Amgen INC. | $171.69 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $163.66 | 2020-2024 | Aralast, Glassia |
| Insmed, INC. | $125.92 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $122.23 | 2021-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $105.57 | 2019 | |
| Jazz Pharmaceuticals INC. | $93.70 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Seelagy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.